Tech Review reports on a new study from the Journal of Clinical Oncology that provides a link between personalized medicine and better health outcomes. For the study, oncologist Lecia Sequist genetically screened patients' lung cancers and then administered a drug tailored for that type of tumor — and those patients did better than the average chemotherapy outcomes. In particular, the study looked at AstraZeneca's Iressa, an EGFR inhibitor.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.